LENALIDOMIDE TEVA 20 mg, hard capsule 21 capsules
Active ingredients: Lercanidipine hydrochloride, LÉNALIDOMIDE
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule21 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LENALIDOMIDE TEVA 20 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 21 plaquette(s) prédécoupées unitaires OPA : polyamide orienté aluminium PVC-Aluminium de 1 gélule(s)
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 28 Mar 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65055820CIP73023485CIP133400930234853Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE LÉNALIDOMIDE HYDRATÉgélule | — | SA |
| LÉNALIDOMIDEgélule | 20 mg · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.